Multifactorial treatment of hypertensive men at high cardiovascular risk and low-density lipoprotein cholesterol affinity to human arterial proteoglycans

European Journal of Clinical Investigation

Volumn 26, Issue 11, 1996, Pages 960-965

  Fagerberg, B ^a   Wiklund, O ^b   Agewall, S ^a   Camejo, G ^c   Wikstrand, R J ^b  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c ASTRAZENECA R AND D   (Sweden)

Author keywords

Atherosclerosis; Diet; Hyperlipidaemia; Hypertension; Intervention; Proteoglycan

Indexed keywords

LOW DENSITY LIPOPROTEIN; PROTEOGLYCAN;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DIET; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SMOKING;

EID: 0029854157     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2362.1996.2030543.x     Document Type: Article

References (23)

1. Wight TN. Cell biology of arterial proteolgycans. Arteriosclerosis 1989;9:1-20.
2. Williams KJ, Tabas I. The response-to-retention hypothesis of early atherogenesis. Arterioscl Tromb 1995;15:551-61.
3. Camejo G, Hurt E, Bondjers G. Effects of proteoglycans on lipoprotein-cell interactions: possible contribution to atherogenesis. Curr Opinion Lipidol 1990;1:431.
4. Hurt-Camejo E, Camejo G, Rosengren B, Lopez F, Wiklund O, Bondjers G. Differential uptake of proteoglycan-selected subfractions of low density lipoprotein by human macrophages. J Lipid Res 1990;31:1387-98.
5. Camejo G, Lindén T, Olsson U, Wiklund O, Lopez F, Bondjers G. Binding parameters and concentration control the formation of complexes between LDL and arterial proteoglycans in serum. Atheroslclerosis 1989;79:121-8.
6. Eisenberg S, Gabvish D, Oschry Y, Fainaru M, Decklebaum RJ. Abnormalities in very low, low and high density lipoproteins in hypertriglyceridemia. Reversal toward normal with bezafibrat treatment. J Clin Invest 1984;74:470-82.
7. Tsai MY, Yuan J, Hunninghake DB. Effect of gemfibrozil on composition of lipoproteins and distribution of LDL subspecies. Atherosclerosis 1992;95:35-42.
8. Agewall S, Fagerberg B, Samuelsson O et al. Multiple cardiovascular risk factor intervention in treated hypertensive men: what can be achieved? Nutr Metab Cardiovasc Dis 1993;3:128-35.
9. Agewall S, Wikstrand J, Samuelsson O, Persson B, Andersson OK, Fagerberg B. The efficacy of multiple risk factor intervention in treated hypertensive men during long-term follow up. J Intern Med 1994;236:651-9.
10. Wilhelmsen L, Berglund G, Elmfeldt D et al. The multifactorial primary prevention trial in Göteborg, Sweden. Eur Heart J 1986;7:279-88.
11. National Cholesterol Education Program expert panel. Report of the national cholesterol education program expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. Arch Intern Med 1988;148:36-69.
12. Agewall S, Fagerberg B, Attval S et al. Microalbuminuria, insulin sensitivity and haemostatic factors in non-diabetic treated hypertensive men. J Intern Med 1995;237:195-203.
13. Beckman-Suurküla M, Wikstrand J, Berglund G, Sivertsson R. Body weight is more important than family history of hypertension for left ventricular function. Hypertension 1991;17:661-8.
14. Lindén T, Bondjers G, Camejo G, Bergstrand R, Wilhelmsen L, Wiklund O. Affinity of LDL to a human arterial proteoglycan among male survivors of myocardial infarction. Eur J Clin Invest 1989;19:38-44.
15. Friedwald WT, Levy RL, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of the preparative ultacentrifuge. Clin Chem 1972;18:499-502.
16. Camejo G, Lopez A, Lopez F, Quinones J. Interaction of low density lipoproteins with arterial proteoglycans. The role of charge and sialic acid content. Atherosclerosis 1993;55:93-105.
17. Auerbach BJ, Parks JS, Aplebaum-Bowden D. A rapid and sensitive microassay for the enzymatic determination of plasma lipoprotein cholesterol. J Lipid Res 1990;30:738-42.
18. Lindén T, Camejo G, Wiklund O, Warnold I, Olofsson S-O, Bondjers G. Effect of short-term beta blockade on serum lipid levels and on the interaction of LDL with human arterial proteoglycans. J Clin Pharmacol 1990;30:5124-131.
19. Camejo G, Lalaguna F, Lopez F, Starosta R. Characterization and properties of a lipoprotein-complexing proteoglycan from human aorta. Atherosclerosis 1980;35:307-20.
20. Reaven GM, Ida Chen Y-D, Jeppesen J, Maheux P, Krauss RM. Insulin resistance and hyperinsulinemia in individuals with small, dense, low density lipoprotein particles. J Clin Invest 1993;92:141-6.
21. Attwall S, Fowelin J, Lager I, von Schenk H, Smith U. Smoking induces insulin resistance - a potential link with the insulin resistance syndrom. J Intern Med 1993;233:327-32.
22. Reaven G. Role of insulin resistance in human disease. Diabetes 1988;37:1595-1607.
23. Wiklund O, Bondjers G, Wright I, Camejo G. Insoluble complex formation between LDL and arterial proteoglycans in relation to serum lipid levels and effects of lipid lowering drugs. Atherosclerosis 1996;119:57-67.